Aktienanalyse zu Galmed Pharmaceuticals Ltd (GLMD)GLMDGalmed Pharmaceuticals Ltd

EoCene Ltd., formerly Galmed Pharmaceuticals Ltd., is an Israel-based healthcare technology and biopharmaceutical company engaged in the development of therapeutic products, medical devices, and healthcare technologies. The Company focuses on gastrointestinal diseases, gastrointestinal oncology, and related medical conditions through a portfolio of pharmaceutical and medical device programs. Its activities include research, development, clinical evaluation, and commercialization of therapeutic candidates and medical technologies. The Company’s portfolio includes Aramchol, a therapeutic candidate for liver and oncology-related indications, and medical device technologies developed through its subsidiary Colospan Ltd. for gastrointestinal and colorectal applications. EoCene Ltd. conducts its operations through biopharmaceutical, medical device, and healthcare technology activities. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Galmed Pharmaceuticals Ltd is not a good buy right now due to its declining stock performance and negative financial indicators. The current price is $3.88, with a year-to-date change of -41.06% and a one-year change of -64.60%. Additionally, the company reported a last earnings EPS of -2.86, indicating ongoing losses. The RSI is at 33.289, suggesting the stock is oversold but may not recover soon given the persistent negative net income figures, such as -4,818,000 USD in Q4 2025. The main risk is the continued negative earnings trend, which has resulted in a forward P/E ratio of 0, indicating no earnings growth is expected in the near future.

5 analysts cover GLMD: 5 rate it Buy, 0 Hold and 0 Sell.